- Home
- PLXS vs CRNX Comparison
PLXS vs CRNX Comparison
Compare PLXS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- CRNX
- Stock Information
- Founded
- PLXS 1979
- CRNX 2008
- Country
- PLXS United States
- CRNX United States
- Employees
- PLXS N/A
- CRNX N/A
- Industry
- PLXS Electrical Products
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- CRNX Health Care
- Exchange
- PLXS Nasdaq
- CRNX Nasdaq
- Market Cap
- PLXS 3.7B
- CRNX 2.8B
- IPO Year
- PLXS 1986
- CRNX 2018
- Fundamental
- Price
- PLXS $138.26
- CRNX $34.20
- Analyst Decision
- PLXS Strong Buy
- CRNX Strong Buy
- Analyst Count
- PLXS 5
- CRNX 7
- Target Price
- PLXS $154.50
- CRNX $74.33
- AVG Volume (30 Days)
- PLXS 131.8K
- CRNX 1.1M
- Earning Date
- PLXS 10-22-2025
- CRNX 11-11-2025
- Dividend Yield
- PLXS N/A
- CRNX N/A
- EPS Growth
- PLXS 47.80
- CRNX N/A
- EPS
- PLXS 5.87
- CRNX N/A
- Revenue
- PLXS $4,025,169,000.00
- CRNX $1,392,000.00
- Revenue This Year
- PLXS $3.54
- CRNX $489.51
- Revenue Next Year
- PLXS $8.05
- CRNX $661.93
- P/E Ratio
- PLXS $23.58
- CRNX N/A
- Revenue Growth
- PLXS 2.31
- CRNX 0.51
- 52 Week Low
- PLXS $103.43
- CRNX $24.10
- 52 Week High
- PLXS $172.89
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- PLXS 55.50
- CRNX 58.12
- Support Level
- PLXS $135.46
- CRNX $33.42
- Resistance Level
- PLXS $141.24
- CRNX $37.23
- Average True Range (ATR)
- PLXS 2.71
- CRNX 1.48
- MACD
- PLXS -0.08
- CRNX -0.01
- Stochastic Oscillator
- PLXS 63.30
- CRNX 56.59
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.